17亿美元!安斯泰来与Vir Bio共同开发PSMA/CD3 TCE

药研界面
Feb 25

2026年2月23日,Astellas和Vir Biotechnology宣布已达成全球战略合作,以推进Vir-5500,这是一种靶向PSMA的PRO-XTEN®双重掩蔽CD3 T细胞接合器(TCE),用于治疗前列腺癌。该合作旨在加速VIR-5500的开发,并进一步加强Astellas的肿瘤管线和前列腺癌症领导地位。来源:Astellas官网尽管近年来治疗手段有所进步,前列腺癌,尤其是转移性去势...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10